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Abstract. Eosinophilic gastrointestinal disorders (EGIDs) affect various segments of the gastrointestinal tract. Since these
disorders are rare, collaboration is essential to enroll subjects in clinical studies and study the broader population. The Rare
Diseases Clinical Research Network (RDCRN), a program of the National Center for Advancing Translational Sciences
(NCATS), funded the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) in 2014 to advance the
field of EGIDs. CEGIR facilitates collaboration among various centers, subspecialties, patients, professional organizations
and patient-advocacy groups and includes 14 clinical sites. It has successfully initiated two large multi-center clinical studies
looking to refine EGID diagnoses and management. Several pilot studies are underway that focus on various aspects of EGIDs
including novel therapeutic interventions, diagnostic and monitoring methods, and the role of the microbiome in pathogenesis.
CEGIR currently nurtures five physician-scholars through a career training development program and has published more
than 40 manuscripts since its inception. This review focuses on CEGIR’s operating model and progress and how it facilitates
a framework for exchange of ideas and stimulates research and innovation. This consortium provides a model for progress
on other potential clinical areas.
Keywords: Eosinophilic diseases, collaborations, rare diseases, multicenter consortium
Eosinophilic gastrointestinal disorders (EGIDs) are a heterogeneous group of inflammatory con-
ditions affecting various segments of the gastrointestinal tract, such as the esophagus, stomach,
small intestine and colon, referred to as eosinophilic esophagitis (EoE), eosinophilic gastritis (EG),
eosinophilic enteritis (EE), and eosinophilic colitis (EC), respectively. The term eosinophilic gastroen-
teritis (EGE) is generally reserved for EGIDs that affect the stomach and intestine and/or esophagus.
The unifying feature of this group of conditions, as the name implies, is eosinophil-predominant
inflammation. Under healthy conditions, eosinophils account for a small fraction of peripheral blood
leukocytes and resident tissue cells. By contrast, eosinophils accumulate in large numbers in the tissues
in patients with EGIDs [37, 38, 44].
Diagnosing EGIDs can be a challenge for three primary reasons. First, the pathology of EGIDs
most likely extends beyond the gastrointestinal epithelium, but the depth of involvement is often
difficult to ascertain due to the limited size and depth of endoscopically obtained biopsies. Second,
histologic assessment of EGE and EC may be confounded by the presence of resident eosinophils in
non-diseased gastrointestinal mucosa. Consensus has not been achieved on optimal cutoff values to
confidently establish normal variations in eosinophil density [20, 40]. The esophagus is an exception
since eosinophils are absent in the healthy esophagus, making histologic assessment of EoE less
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challenging [40]. Finally, increased numbers of mucosal/epithelial eosinophils are not pathognomonic
for EoE, EGE, or EC, as mucosal eosinophilia can be seen in other diseases including reflux esophagitis,
parasitic infestations, rheumatologic conditions, and inflammatory bowel disease [25, 45]. The current
proposed diagnostic criteria used by CEGIR for EG, EGE, and EC entails histologic findings of at
least twice the upper limit of normal for eosinophils per high-power field (HPF) reported in affected
segments of the gastrointestinal tract [6, 26, 27].
Patient advocacy groups (PAGs) are also increasing national attention for these disorders with
calls for National Institutes of Health (NIH) research funding and government support (e.g. National
Eosinophil Awareness Week unanimously passed by the USA House of Representatives in 2007).
A needs assessment survey conducted by CEGIR and its associated PAGs found that a significant
majority of patients felt that there was not enough awareness regarding EGIDs in school and workplace
(78% and 67%, respectively) [16].
Because EGIDs are rare, collaboration is essential not only to increase the number of subjects
participating in clinical studies, but also to clarify whether findings from individual sites are valid
in a broader population. Over the years, though the literature has slowly blossomed, investigators
have mostly collaborated on a regional basis with limited intra- and inter-center communications.
CEGIR, under the auspices of the Rare Disease Clinical Research Network (RDCRN), an initiative
of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational
Sciences (NCATS), NIH, was established in 2014 to overcome these handicaps and facilitate research
and training on EGIDs. This report highlights the work of CEGIR and describes the framework needed
to establish a multi-center consortium required to study the social, financial, and medical burden;
diagnostic criteria; and the best treatment regimens that rare diseases such as EGIDs have.
1. Structure
CEGIR is one of 21 multi-site consortia of RDCRN. RDCRN is an initiative established in 2003
and funded by ORDR, NCATS, and collaborating institute centers. Its main focus is to promote
multi-site clinical research, foster collaborations, and generate publications to both advance science
and raise awareness on rare diseases. The RDCRN has studied more than 200 rare diseases since its
inception [2, 23, 30]. CEGIR comprises nine primary academic centers in California, Colorado, Illinois,
Massachusetts, North Carolina, Ohio, and Pennsylvania, as well as secondary centers in Arkansas,
Minnesota, New York, Tennessee, and Utah and an advisory site in Switzerland (Fig. 1). These centers
were chosen based on previous collaboration, ability to integrate pediatric and adult patients into a
Fig. 1. CEGIR Centers.
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Fig. 2. CEGIR Emblem: The C is in the shape of a nucleus of an eosinophil, which defines this group of disorders.
common consortium, and access to patients with these rare diseases. Each of the primary sites has
a CEGIR site-investigator. These physicians provide diverse expertise in relevant clinical specialties
including gastroenterology, allergy, immunology, and pathology in both adult medicine and pediatrics.
In addition to these individuals, CEGIR also includes a project scientist from NIH institute centers,
the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK), and NCATS, as a collaborator. The mission of CEGIR
is to improve the lives of individuals with EGIDs through innovative research, clinical expertise, and
education via collaborations between scientists, physicians, patients, and professional organizations.
Figure 2 summarizes the interacting components of CEGIR.
Prior to the formation of CEGIR, many of these researchers worked collaboratively as founders
of The International Gastrointestinal Eosinophil Researchers (TIGERs) and co-authored numerous
publications. Most notably, these investigators were involved in forming the first consensus recom-
mendations for diagnosis and treatment of EoE in 2007 (14) and its subsequent update in 2011 (6).
The RDCRN program funding and designation provided a means for collaborating investigators to
increase their interaction, enroll patients into registries, test hypotheses that have been developing over
the past decade, and leverage NIH networks and expertise to advance the understanding and treatment
of EGIDs, ultimately improving the lives of patients with EGIDs. CEGIR is co-funded by NCATS,
NIDDK, and NIAID through a cooperative agreement award.
Collaborations with PAGs as research partners is a requirement and a unique feature of the RDCRN
program. CEGIR includes many PAGs as research partners, including the American Partnership for
Eosinophilic Diseases (APFED, www.apfed.org), Campaign Urging Research for Eosinophilic Dis-
ease (CURED, www.cured.org), and the Eosinophilic Family Coalition (EFC, www.eoscoalition.org).
These PAGs work to educate patients and support research aimed at improving treatment and cures
for eosinophil-associated diseases and their complications. They have a crucial role within CEGIR
in identifying and recruiting patients for clinical research. Notably, APFED and CURED have exten-
sive patient databases through which they can regularly communicate with and identify patients who
might be eligible for enrollment in CEGIR-sanctioned research initiatives. APFED and CURED also
contribute financially to CEGIR.
The CEGIR Administrative Unit (Fig. 3) is spearheaded by a Principal Investigator, Program
Director, and the Internal CEGIR Steering Committee, which has representation from CEGIR site-
investigators, PAGs, and professional medical research groups. The CEGIR Administrative Unit
generates and administers policies, procedures, and communications and distributes the funds asso-
ciated with CEGIR. In addition, the CEGIR External Advisory Board (EAB) oversees the overall
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Fig. 3. CEGIR Administrative Unit.
functioning of the consortium and is composed of individuals with recognized expertise in the medical
community. The CEGIR EAB assists by providing an external and objective performance review of
the CEGIR initiatives in the realms of research, training, administration, individual site performance,
and expansion to other medical research centers.
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Table 1
Current projects in CEGIR
Core Project title Disease Primary Investigators Primary Site
Clinical Trial A Prospective, Multicenter Study
to Compare and Validate
Endoscopic, Histologic,
Molecular, and
Patient-Reported Outcomes in
Pediatric and Adult Patients
with EoE, EG and EC
(OMEGA)
EoE, EG,
EC
Drs. Glenn Furuta and Seema
Aceves
Children’s Hospital
Colorado and
University of
California,
San Diego
Six versus One Food EoE
Elimination Diet followed by
Swallowed Glucocorticoid
Trial (SOFEED)
EoE Drs. Marc Rothenberg, Ikuo
Hirano and Jonathan Spergel
Cincinnati Children’s
Hospital
Pilot A preliminary open-label trial of
losartan potassium in
participants with EoE with or
without a connective tissue
disorder
EoE Drs. Marc Rothenberg and Pablo
Abonia
Cincinnati Children’s
Hospital
Role of Microbiome in EoE, EG
and EC
EoE, EG,
EC
Dr. Sophie Fillon Children’s Hospital
Colorado
Use of unsedated transnasal
esophagoscopy to monitor
dietary management of EoE
EoE Dr. Joel Friedlander Children’s Hospital
Colorado
Prospective trial of elemental
diet in adults with EG
EG Dr. Nirmala Gonsalves Northwestern
University
Contact Registry Contact Registry Dr. Pablo Abonia
Training Demographics, clinical
characteristics, and pathology
of EG and EC in a multi-site
cohort
Dr. Robert Pesek Arkansas Children’s
Validation of online cohort of
patients with EGIDs enrolled
in CEGIR Contact Registry
Dr. Girish Hiremath Arkansas Children’s
There are three main components to CEGIR: Clinical Research Projects for Observa-
tional/Longitudinal Studies (further divided into Project 1 and Project 2), Pilot/Demonstration Clinical
Research Program, and Training (Career Development) Program. In addition, there is a Contact Reg-
istry (Table 1). Each of these cores has a project lead and associate project lead who both conduct
studies in conjunction with the Internal CEGIR Steering Committee. They also report to the CEGIR
Administrative Unit and CEGIR EAB, which then report to the RDCRN Steering Committee.
Regular communications between the CEGIR Administrative Unit and other CEGIR investigators
occurs on a biweekly basis, on different days and times so as to maximize participation. The CEGIR
Administrative Unit also communicates with the CEGIR EAB via semiannual conference calls and by
an annual written report. In addition to these regular communications, CEGIR holds an annual meeting,
where all investigators, clinical research coordinators, NIH Institute Center Officer and Project Scientist
collaborators, PAGs, and other stakeholders involved in CEGIR are invited to attend. The first three
annual meetings have been held in conjunction with professional society meetings and have involved
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Fig. 4. CEGIR members at recent meeting in Atlanta on March 2017.
a growing number of broad participants, numbering over 70 individuals in the third meeting. Figure 4
shows the convened group for the most recent meeting.
CEGIR complies with all applicable research ethical standards and has a central Institutional Review
Board (cIRB) that can review and monitor its various projects. The formation of a cIRB allows multi-
center studies to proceed more efficiently. Instead of each institution going through its own IRB
reviews, this process streamlines the research administrative process through previously developed
inter-institutional agreements that comply with all local IRBs. The cIRB is located at the Cincinnati
Children’s Hospital Medical Center (CCHMC).
CEGIR investigators closely collaborate with the RDCRN Data Monitoring Coordinating Center
(DMCC) for a variety of activities including the development of protocol electronic case report forms
(CRFs). The DMCC provides monitoring instruments (e.g. compliance reports) enabling CEGIR to
monitor the collection of data by protocol and ensure quality data are being obtained. Data collected
through CEGIR is maintained at the DMCC, which serves as the primary data-housing center of
CEGIR. There is regular communication between CEGIR and members of the DMCC. The DMCC is
particularly helpful in developing templates for protocols and works closely with the medical offi-
cer (from NIAID) of CEGIR and the investigators to ensure data compliance and generate data
reports.
2. Clinical Research Projects for Observational/Longitudinal Studies
This component has two projects that were established to define diagnostic and clinical features of
these disorders, validate clinical outcome metrics, identify biomarkers and optimize therapy.
2.1. Clinical Research Project 1: Outcome Measures for Eosinophilic Gastrointestinal Diseases
Across Ages (OMEGA)
This prospective, multi-center study aims to determine the best tools for diagnosing and monitoring
disease characteristics. It seeks to compare and validate endoscopic, histologic, molecular, and patient-
reported outcomes in both pediatric and adult patients with EoE, EG, and EC at various points of clinical
care with longitudinal follow-up and biospecimen acquisition (Fig. 5).
At present, tissue eosinophil counts are considered the reference standard for diagnosing and moni-
toring EGIDs, yet there is no consensus regarding the correlation between this parameter and clinical
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Fig. 5. Diverse biospecimens being collected and studied as part of CEGIR.
symptoms [15]. CEGIR investigators and others have developed some clinical outcome metrics (COM),
which are instruments to objectively measure patient-reported outcomes, quality of life, and endoscopic
findings [8, 28, 41]. This study hypothesizes that peak mucosal eosinophil levels correlate with COM
findings. In addition, the study also tests the hypothesis that inflamed tissues of EGIDs express unique
messenger RNA transcript profiles and that elucidating these molecular profiles will both advance
the understanding of these enigmatic disease and provide molecular criteria for disease diagnosis and
monitoring. With the large database of biopsy specimens collected through this program, researchers
can seek to identify gene expression profiles in the tissues of EoE, EG, and EC to differentiate these
disorders from one another and from control subject biopsies. The results of such comprehensive
databases are generating clinical outcome metrics for EoE, EG, and EC and defining basic clinical,
laboratory, and pathologic features of EG and EC.
At this time, more than 700 patients have been enrolled in the study throughout the USA. The study
also aims to procure endoscopic biopsies at the time of enrollment and to review the first diagnostic
endoscopy. Clinic visits, endoscopies, and other interventions done as part of standard of care for
monitoring are captured prospectively together, with patient/family/provider-completed questionnaires
to assess patient-reported outcomes such as symptoms. This project aims to provide more information
on monitoring disease severity by correlating COM with clinical criteria. A biorepository composed
of blood and tissue samples, including sera, plasma, DNA, and tissue RNA, is being collected; the
biorepository currently contains over 4000 samples.
2.2. Clinical Research Project 2: Six Food vs One Food Eosinophilic Esophagitis Elimination
Diet (SOFEED)
This is a prospective, randomized trial to evaluate the effects of a diet with fewer restrictions than
currently recommended for EoE. It also seeks to determine the response to swallowed steroid therapy
in patients who experience diet failure. Answering this question was deemed important by the PAGs
and was thus prioritized as an initial major study of CEGIR.
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Dietary antigen exposure is an important driving force for the pathogenesis of EoE as this disorder
is often reversible following appropriate elimination of triggering food groups [21]. Both skin test-
directed and six-food elimination diet (6FED) approaches have been shown to be ∼70% effective
[19, 42]. The 6FED includes removing milk, egg, wheat, soy, nuts (peanuts/tree nuts), and seafood
(fish/shellfish). This study compares 1FED (avoidance of milk) versus 6FED (avoidance of all 6
aforementioned foods) in adult patients and is currently in the recruitment phase, with 75 of 126
patients enrolled. Patients are randomly assigned to one of the two diets at each participating CEGIR
site. There is standardization across the various sites by providing consensus documents and links
to instructional videos on diet information. Dieticians across the centers communicated and together
developed these standardized documents and educational materials for patients. Patients whose disorder
is in histologic remission (<15 eosinophils/HPF) at 6 weeks are deemed to have completed the study.
Those whose disorder remains inflamed (≥15 eosinophils/HPF) at that time continue with the study;
those who were initially in the 1FED group are reassigned to the 6FED diet, and those already on
the 6FED group start swallowed glucocorticoid therapy in a standardized dose and are monitored
for another 6 weeks. All patients undergo endoscopy with biopsies at the end of the study to look
for endoscopic and histologic outcomes. Endpoints in this study include the percentage of patients
whose disorder evidences histologic remission, distribution of patients within a histology-based scoring
system (including remodeling markers), and changes in COM.
3. Pilot/Demonstration Clinical Research Program
The Pilot/Demonstration Clinical Research Program supports new ideas by sponsoring pilot projects.
The pilot research projects address novel areas of research pertaining to EGIDs. The projects may be
collaborative among investigators at one or more CEGIR sites or with investigators outside of the
CEGIR network.
The selection process aims to optimize CEGIR involvement and collaboration to enable the pursuit
of potentially novel hypotheses to study these rare disorders. The Internal CEGIR Steering Committee
meets every 6 months to review applications and monitor the progress of current projects. Proposals
received are ranked according to specific criteria based on scientific merit, likelihood of success, ability
to develop synergy with other investigators or ongoing projects in CEGIR, use of existing clinical and
biological materials, novel approaches, development of biomarkers, and potential for partnership with
commercial entities such as pharmaceutical companies and PAGs. These criteria concur with the
goals of the NIH Taskforce on Research Needs of Eosinophil-Associated Diseases (TREAD) [10]
and those identified through discussions with the Food and Drug Administration Meetings, [39] both
of which detail a number of unmet needs for EGIDs. The project leaders and the Internal CEGIR
Steering Committee, with the help of other CEGIR investigators, a representative of the International
Eosinophil Society, and PAG representatives, meet to make the final selection(s).
Since 2014, four pilot projects have been chosen and are in various stages of development
(Table 1). These projects were selected from 13 submissions and thus represent a competitive review
process.
One of the pilot projects is the creation and analysis of a centralized microbiome database for EoE,
EG, and EC based on tissue biopsies as well as stool samples. This unique project aims to use CEGIR’s
network to collect more specimens to better understand the microbiome of patients with EGIDs and
its association with treatment and prognosis. Microbiome content of stool samples has the potential
to be a non-invasive biomarker for disease diagnosis and monitoring. Previous studies observed dif-
ferences in the microbiome of patients with EoE, but it is unclear how this is associated with patient
outcomes [31].
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Another project focuses on a preliminary, open-label trial of losartan in patients with EoE with or
without a connective tissue disorder. This project is based on previous observations that TGF- is
overexpressed in EoE and that mutations in TGF- receptors have been associated with increased risk
of EoE [1, 36]. These and other findings, including studies in mice, have prompted analysis of the
clinical effectiveness of losartan, as one of its effects is to lower TGF- levels.
The third study is focused on the use of unsedated transnasal esophagoscopy (TNE) to monitor
EoE disease activity [11]. Since TNE does not require the use of either moderate sedation or general
anesthesia, it has the potential to lessen patient inconvenience and cost and potentially provide an
opportunity for research with the ability to perform more frequent and less invasive monitoring.
Finally, a prospective trial of elemental diet therapy for adult patients with EG is being undertaken.
This study will provide prospective evidence that EG is an antigen-driven disorder and will provide
evidence for the clinical use of an elimination diet in the treatment of non-EoE EGIDs.
4. Contact registry
In 2015 in collaboration with the RDCRN-DMCC, CEGIR launched the Patient Contact Registry,
an interactive tool for patients with EGIDs. The DMCC maintains the contact registry, tracks its usage,
and provides its own regulatory pathway for querying the contact registrants. The resulting centralized
database allows CEGIR investigators to identify and recruit patients to new clinical studies. Upon
enrollment, each patient is invited to complete a questionnaire to capture his or her disorder information.
This allows collection of data on diagnosis, tests, and management from a diverse and large cohort
of patients with EGIDs from all around the world. More importantly, it provides a portal to enrolled
patients and families with updates on the disorders and opportunities to learn more about the various
clinical trials available. Almost 1,100 patients from more than 20 countries have enrolled in the CEGIR
Patient Contact Registry. This registry provides an extension of CEGIR’s network beyond the current
sites and helps CEGIR achieve its goal of obtaining access to a population more representative of
the affected population. CEGIR seeks to use its contact registry as a powerful platform for its EGID
research. CEGIR is also conducting a validation study of the Contact Registry data through a project
being conducted by one of its trainees (see Table 2).
5. Training (Career Development) Program
The CEGIR resources and opportunities available at each site create an opportunity to train new
investigators in clinical and translational research focusing on EGIDs. After its formation in 2014,
a call for applications was advertised to all fellows and junior faculty in various fields including
gastroenterology, allergy/immunology, and pathology and spanning pediatrics and internal medicine
specialists. The selection committee includes training section co-leads, as well as CEGIR PI and
PAG representatives. The committee ranks applicants on the basis of academic background and the
likelihood that candidates will continue to pursue EGID-related research after the grant’s conclusion.
Since 2014, five CEGIR trainees have been selected from 31 applicants, and there are several active
projects being spearheaded by these trainees (Table 2). Three of the current physician-trainees are or
have been supported by NIH K08 grants.
The Training (Career Development) Program takes advantage of CEGIR resources and opportuni-
ties available at each site to create an environment that trains new investigators not only in clinical
research, but also in the challenges common to the research of rare diseases through a series of lec-
tures, webinars, and discussions. Each trainee has a variety of resources and opportunities available at
each of the CEGIR sites to enhance likelihood of academic success and career development, such as
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Table 2
CEGIR Trainees
Trainee Mentor Institution Appointment Research Interest Other NIH
funding
Patricia
Fulkerson
Marc Rothenberg Cincinnati Children’s
Hospital
April 2015 Eosinophil progenitors
and EGIDs in pediatric
patients after solid organ
transplant
K08, R01
Robert Pesek Evan Dellon Arkansas Children’s
Hospital and
University of
Arkansas for
Medical Sciences
April 2015 Pathology of EG and EC
Girish
Hiremath
Pablo Abonia and
Evan Dellon
Vanderbilt University August 2015 Assessing the needs of
individuals with EGIDs
through the CEGIR
Contact Registry
Amanda
Muir
Jonathan Spergel The Children’s
Hospital of
Philadelphia
August 2015 Measurement of stretch of
esophagus as potential
for detection of pediatric
fibrosis and stricture in
EoE
K08
Joshua
Wechsler
Ikuo Hirano and
Bruce Bochner
Northwestern
University
August 2016 The role of mast cells in
EoE
K08
RDCRN support, training-specific institutional resources, partnership with PAGs, access to 21 teach-
ing videos/presentations prepared by CEGIR investigators and now available online (https://www.rare
diseasesnetwork.org/cms/cegir/Learn-More/Educational-Videos), and the breadth and depth of the
expertise of the CEGIR investigators in clinical research and mentorship.
6. Pathology Core
With the large number of biopsies collected through various studies and the microbiome program,
CEGIR also has a corresponding CEGIR Pathology Core that reviews the relevant slides for eosinophil
density and other pathologic features. A team of pathologists provides invaluable skills, such as
immunohistochemistry and electron microscopy. The CEGIR Pathology Core uses a Virtual Micro-
scope platform to ease the protected process of collecting and transferring specimen images across
the country. Whole-slide scanned images, deposited in permissions-restricted Dropbox, are provided
for central pathology review. For sites that do not have slide-scanning capability, slides are sent to
CCHMC and are scanned into a secure, cloud-based document CEGIR site.
7. Publications Committee
The creation of the CEGIR Publications Committee has helped CEGIR publish more than 40 journal
articles in the short time since its inception. This committee facilitates the timely reporting of study
results through support to the primary authors. A wide variety of publications has emerged from
CEGIR including review articles, [12, 14, 18, 29] editorials, and original research articles. Research
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published thus far has focused on a wide range of topics including disease mechanisms, [4, 5, 13,
24, 31] pathology and histology, [32, 33, 35] diagnosis, [7] and various treatment options for EGIDs
including steroids, [17, 34] diet changes, [3, 43] and proton pump inhibitors [9, 22]. CEGIR and
its Publications Committee will continue to report new findings, especially as the ongoing trials and
projects supported by CEGIR are completed.
Summary
CEGIR, as a part of RDCRN, is a consortium created to promote collaboration among pediatric and
adult academic research centers and PAGs. Importantly, the group provides a platform for collecting
longitudinal data and specimens into centralized databases, thereby improving clinical management and
understanding of EGIDs. Its success is predicated on synergy between multiple experts in various fields,
which has translated to successful projects, more than 40 publications, and the rapid exchange of the
best patient treatment methods since its formation. The PAGs have been important and core participants
of CEGIR and contribute to its activities including its research agenda. The opportunities afforded by
the CEGIR network, as compared with other traditional collaborative and/or grant mechanisms, are
numerous as detailed in Table 3.
There are multiple steps that led to the creation of CEGIR. They started by identifying stakehold-
ers such as key specialists, experts, and interest groups. The core group was composed of motivated
individuals who had a common goal and were willing to collaborate. This group had frequent com-
munication aiming to clearly define the consortium’s vision and objectives. After its initial set-up
phase, the strength of the consortium was defined by its ability to evolve and provide its members
with a mutually beneficial relationship. This in itself was spearheaded by a clearly defined structure
allowing for both internal and external reviews at regular intervals to provide objective and continuous
evaluation of the consortium’s goals, as it is important to continuously evaluate the various projects
Table 3
CEGIR: Benefits and lessons learned
Benefit Comment
Funding $1.2 million of annual funding is provided by NIH
Collaborations Enhanced collaborations between multiple and varied stake-holders
Leverages other funding mechanisms Co-funding provided by select institutions including PAGs
Unifies different stakeholders within the field Brings together PAG and Researchers and NIH Institute Centers
Interaction with other consortia in network Sharing of research platforms
Data management and coordination RDCRN provides this service as part of the participation. The DMCC
allows CEGIR to leverage a number of services not normally available
to stand-alone grants.
Support for trainees Trainees benefit from participating in CEGIR clinical studies, can utilize
CEGIR-generated research resources, and can participate in
RDCRN-wide training programs
Provides infrastructure upon which other
studies are built
Registries provide resource for other studies
Partnership and engagement of expertise of
NIH
U54 grant mechanism is a Cooperative Agreement and benefits from
interaction with NIH experts including Medical Officer, Project
Scientists, Program Officers, Data and Safety Monitoring Board
(DSMB), and others
Develops uniform processes and consensus
opinions and approaches
Examples include central pathology review and standard operating
manual for common procedures such as skin testing.
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within the consortium in order to identify weaknesses, correct flaws, and build upon strengths. Besides
research, the training component is essential to stimulate, promote, and nurture the next generation of
investigators’ interest in the field.
Although still in its early stage, CEGIR has already enabled the study of a group of rare diseases
through the creation of a collaborative environment and opportunities to participate and generate
numerous research projects. The cohesiveness and productivity within this consortium, along with
lessons learned as outlined in this review, is a model for other potential multi-center consortia.
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